Hipertensión arterial refractaria

2003, 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J Hypertens, 21, 1011, 10.1097/00004872-200306000-00001 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-72. Marín, 2005, Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005, Med Clin (Barc), 125, 24, 10.1157/13076402 Griffith, 2005, Systolic hypertension: an overview, Am Heart J, 149, 769, 10.1016/j.ahj.2005.01.037 Marín, 2005, Guía Española de Hipertensión Arterial 2005. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA), Hipertension, 22, 1 Alderman, 1988, Prevalence of drug resistant hypertension, Hypertension, 11, II71 Erdine, 2003, Arat-Özkan Resitant hypertension. European Society Scientific Newsletter, Update on Hypertension management, 4, 15 Swales, 1982, Treatment of refractory hypertension, Lancet, 1, 894, 10.1016/S0140-6736(82)92162-6 Gifford, 1978, Resistant hypertension: diagnosis and management, Ann Intern Med, 88, 661, 10.7326/0003-4819-88-5-661 Yakovlevitch, 1991, Resistant hypertension in a tertiary care clinic, Arch Intern Med, 151, 1786, 10.1001/archinte.1991.00400090078014 Mejía, 1990, Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension, Ann Intern Med, 112, 270, 10.7326/0003-4819-112-4-270 Coca Payeras, 2005, Evolución del control de la hypertension arterial en Atención Primaria en España. Resultados del studio Controlpress 2003, Hipertension, 22, 5, 10.1016/S0212-8241(05)74809-X Banegas, 2002, Hypertension magnitud and management in the elderly population of Spain, J Hypertens, 20, 2157, 10.1097/00004872-200211000-00014 Mitchell, 2005, Evaluation and management of patients with uncontrolled sistòlic hypertension: is another new paradigm really needed?, Am Heart J, 149, 776, 10.1016/j.ahj.2005.01.038 Lloyd-Jones, 2002, Treatment and control of hypertension in the community: a prospective analysis, Hypertension, 40, 640, 10.1161/01.HYP.0000035855.44620.DA Borzecki, 2005, Barriers to hypertension control, Am Heart J, 149, 785, 10.1016/j.ahj.2005.01.047 Lloyd-Jones, 2000, Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community, Hypertension, 36, 594, 10.1161/01.HYP.36.4.594 Setaro, 1992, Refractory hypertension, N Engl J Med, 327, 543, 10.1056/NEJM199208203270808 Flockhart, 2002, Implications of cytochrome P450 interactions when prescribing medication for hypertension, Arch Intern Med, 162, 405, 10.1001/archinte.162.4.405 Morales-Oliva, 2005, Interacciones farmacológicas de los fármacos antihipertensivos, Med Clin (Barc), 124, 782, 10.1157/13075851 Taler, 2002, Resistant hypertension. Comparing hemodynamic management to specialist care, Hypertension, 39, 982, 10.1161/01.HYP.0000016176.16042.2F Garg, 2005, Resistant hypertension revisited: a comparison of two University-based cohorts, Am J Hypertens, 18, 619, 10.1016/j.amjhyper.2004.11.021 Gifford, 1988, An algorithm for the management of resistant hypertension, Hypertension, 11, II101 Burnier, 2001, Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions, J Hypertens, 19, 335, 10.1097/00004872-200102000-00022 Hla, 1991, Observer variability of Osler’s maneuver of pseudohypertension, J Clin Epidemiol, 44, 513, 10.1016/0895-4356(91)90214-T Brown, 2001, Is resistant hypertension really resistant?, Am J Hypertens, 14, 1263, 10.1016/S0895-7061(01)02193-8 Cuspidi, 2001, High prevalence of cardiac and extracardiac target organ damage in refractory hypertension, J Hypertens, 19, 2063, 10.1097/00004872-200111000-00018 Hernández del Rey, 1998, Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect, Blood Press Monit, 3, 331 Mezzetti, 1997, White-coat resistant hypertension, Am J Hypertens, 10, 1302, 10.1016/S0895-7061(97)00318-X Muxfeldt, 2003, Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension, Blood Press Monit, 8, 181, 10.1097/00126097-200310000-00001 Redón, 1998, Prognosis value of ambulatory blood pressure monitoring in refractory hypertension. A prospective study, Hypertension, 31, 712, 10.1161/01.HYP.31.2.712 Isaksson, 1993, Therapy-resistant hypertension associated with central obesity, insulin resistance, and large muscle fibre area, Blood Pressure, 2, 46, 10.3109/08037059309077526 Martell, 2003, High prevalence of secondary hypertension and insulin resístanse in patients with refractory hypertension, Blood Pressure, 12, 149, 10.1080/08037050310009950 Hernández del Rey R, Armario P, Martín-Baranera M, Castellanos P. Elevada agregación de factores de riesgo cardiovascular y de prevalencia de síndrome metabólico en sujetos con hipertensión arterial resistente. Med Clin (Barc) (en prensa). Aguilera, 1999, Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring, Hypertension, 33, 653, 10.1161/01.HYP.33.2.653 Calhoun, 2002, Resistant hypertension, Cure Hypertens Rep, 4, 221, 10.1007/s11906-002-0011-8 Levey, 2003, National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification, Ann Intern Med, 139, 137, 10.7326/0003-4819-139-2-200307150-00013 Peralta, 2005, Control of hypertension in adults with chronic kidney disease in the United States, Hypertension, 45, 1119, 10.1161/01.HYP.0000164577.81087.70 Kaplan, 2005, Resistant Hipertensión, J Hypertens, 23, 1441, 10.1097/01.hjh.0000174968.72212.ac Quan, 2004, Cardiovascular consequences os sleep-disordered breathing: past, present, and future. Report of a Workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute, Circulation, 109, 951, 10.1161/01.CIR.0000118216.84358.22 Flemons, 2002, Obstructive sleep apnea, N Engl J Med, 347, 498, 10.1056/NEJMcp012849 Malhotra, 2002, Obstructive sleep apnea, Lancet, 360, 237, 10.1016/S0140-6736(02)09464-3 Peppard, 2000, Prospective study of the association between sleep-disordered breathing and hypertension, N Engl J Med, 342, 1378, 10.1056/NEJM200005113421901 Grote, 2000, Sleep-related breathing disorder is an independent factor for uncontrolled hypertension, J Hypertens, 18, 679, 10.1097/00004872-200018060-00004 Logan, 2003, Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex, Eur Respir J, 21, 241, 10.1183/09031936.03.00035402 Fletcher, 2003, Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea, Sleep, 26, 15, 10.1093/sleep/26.1.15 Narkiewicz, 1997, The sympathetic nervous system and obstructive sleep apnea: implications for hypertension, J Hypertens, 15, 1613, 10.1097/00004872-199715120-00062 Calhoun, 2004, Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea, Chest, 125, 112, 10.1378/chest.125.1.112 Baguet, 2005, Obstructive sleep apnea and hypertension. European Society of Hypertension Scientific Newsletter, Update on Hypertension management, 6, 25 Marín, 2005, Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study, Lancet, 365, 1046, 10.1016/S0140-6736(05)74229-X Narkiewicz, 1999, Nocturnal continuous positive airway pressure descreases daytime sympathetic traffic in obstructive sleep apnea, Circulation, 100, 2332, 10.1161/01.CIR.100.23.2332 Bonsignore, 2002, Continuous positive airway pressure treatment improves baroreflex control of heart rate during sleep in severe obstructive sleep apnea syndrome, Am J Respir Crit Care Med, 166, 279, 10.1164/rccm.2107117 Gami, 2005, Day-night pattern of sudden death in obstructive sleep apnea, N Engl J Med, 352, 1206, 10.1056/NEJMoa041832 Dhillon, 2005, Sleep apnea, hypertension, and the effects of continuous positive airway pressure, Am J Hypertens, 18, 594, 10.1016/j.amjhyper.2004.11.031 Hermida, 2004, Effect of continuous positive airway pressure on ambulatory blood pressure in patients with obstructive sleep apnoea, Blood Press Monit, 9, 193, 10.1097/00126097-200408000-00004 Caples, 2005, Obstructive sleep apnea, Ann Intern Med, 142, 187, 10.7326/0003-4819-142-3-200502010-00010 Slovut, 2004, Fibromuscular dysplasia, N Engl J Med, 350, 1862, 10.1056/NEJMra032393 Alcázar, 2000, Ischemic nephropathy: clinical characteristics and treatment, Am J Kidney Dis, 36, 883, 10.1053/ajkd.2000.19077 Spence, 2000, Management of resistant hypertension in patients with carotid stenosis: high prevalence of renovascular hypertension, Cerberovasc Dis, 10, 249, 10.1159/000016066 Armario, 2003, Estenosis de arterial renal, hypertension arterial y nefropatía isquémica, Clin Invest Arterioscl, 15, 21 Edwards, 2005, Renovascular disease and the risk of adverse coronary events in the elderly. A prospective, population-based study, Arch Intern Med, 165, 207, 10.1001/archinte.165.2.207 Kaplan, 2004, Current epidemic of aldosteronismo, J Hypertens, 22, 863, 10.1097/00004872-200405000-00001 Martinez Debén, 2004, Es conveniente el despistaje del hiperaldosteronismo en el paciente hipertenso, Hipertensión, 21, 119 Lim, 2002, Is aldosterona the missing link in refractory hypertension? aldosterona-to-renin ratio as a marker or inapropiate aldosterona activity, J Hum Hypertens, 16, 153, 10.1038/sj.jhh.1001320 Armario, 2004, No es necesario el despistaje del hiperaldosteronismo primario en la gran mayoría de los pacientes hipertensos, Hipertensión, 21, 114 Mosso, 2003, Primary aldosteronismo in hypertensive disease, Hypertension, 42, 161, 10.1161/01.HYP.0000079505.25750.11 Strauch, 2003, Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region, J Hum Hypertens, 17, 349, 10.1038/sj.jhh.1001554 Calhoun, 2002, Hyperaldosteronism among black and white subjects with resistant hypertension, Hypertension, 40, 892, 10.1161/01.HYP.0000040261.30455.B6 Mulatero, 2002, Drug effects on aldosterone/plasma renin ratio in primary aldosteronism, Hypertension, 40, 897, 10.1161/01.HYP.0000038478.59760.41 Milliez, 2005, Evidence for an increases rate of cardiovascular events in patients with primary aldosteronismo, J Am Coll Cardiol, 45, 1243, 10.1016/j.jacc.2005.01.015 Verdecchia, 2002, Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects, J Am Coll Cardiol, 39, 878, 10.1016/S0735-1097(01)01827-7 Benetos, 2003, Why cardiovascular mortality is higher in treated hypertensiives versus subjects of the same age, in the general population, J Hypertens, 21, 1635, 10.1097/00004872-200309000-00011 Eide, 2004, Low-renin status in therapy-resistant hypertension: a clue to efficient treatment, J Hypertens, 22, 2217, 10.1097/00004872-200411000-00026 Ouzan, 2002, The role of spironolactone in the treatment of patients with refractory hypertension, Am J Hypertens, 15, 333, 10.1016/S0895-7061(01)02342-1 Nishizaka, 2003, Efficacy of lowdose spironolactone in subjects with resistant hypertension, Am J Hypertens, 16, 925, 10.1016/S0895-7061(03)01032-X Brown, 2003, Eplerenone: cardiovascular protection, Circulation, 107, 2512, 10.1161/01.CIR.0000071081.35693.9A Black, 2004, Evolving role of aldosterona blockers alone and in combination with angiotensina-converting enzyme inhibitors or angiotensina II receptor blockers in hypertension management: a review of mechanistic and clinical data, Am Heart J, 147, 564, 10.1016/j.ahj.2003.10.034